Compare Dyne Therapeutics Inc. Common Stock (DYN) vs MetLife Inc. Common Stock (MET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs MetLife Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while MetLife Inc. Common Stock trades at $100.15 (market cap $63.96B). The key difference: MetLife Inc. Common Stock is far larger — about 22.4× Dyne Therapeutics Inc. Common Stock's market cap, and MetLife Inc. Common Stock pays a 2.35% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and MetLife Inc. Common Stock for 6 Days on average.
| DYN | MET | |
|---|---|---|
Market Cap | $2.86B | $63.96B |
Volume | 3,341,579 | 3,016,459 |
Sector | Health | Financials |
52-Week High | $26.78 | $100.65 |
52-Week Low | $14.60 | $67.70 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $84.89B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MetLife (MET) trades at $100.65, up 0.48% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with a P/E of 19.28 and a net income margin of 4.66%. Recent news highlights a declared dividend of $0.59 per share and upcoming Q3 2026 results.
The outlook for MET is positive, driven by earnings momentum and a favorable interest rate environment for insurers. Key risks include investment income volatility and competitive pressures. With a consensus price target of $108.25 and no sell ratings, Wall Street sentiment remains bullish, though the stock's RSI suggests potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About MetLife Inc. Common Stock
MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →
